Leipzig-based biotech start-up Primogene GmbH has secured €4.1 million in funding to bring complex bioactive molecules to market at scale. Using proprietary enzymatic platform technology, the company produces biomolecules that are identical to their natural counterparts, sustainably, cost-efficiently, and at industrial scale. Primogene serves diverse markets from infant nutrition and adult health to pharmaceutical raw materials and personal care.The seed round is led by High-Tech Gründerfonds (HTGF) with additional investors including Technologiegründerfonds Sachsen (TGFS), better ventures, Sächsische Beteiligungsgesellschaft (SBG), Golzern Holding GmbH, FS Life Science Investment GmbH, and Dr. Marc Struhalla (founder and CEO of c-LEcta GmbH). The new capital will be used to expand the IP portfolio, strategic partnerships, and production capacities.